Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree NV, Manegold C. ten Bokkel Huinink WW, et al. Among authors: bergman b. Lung Cancer. 1999 Nov;26(2):85-94. doi: 10.1016/s0169-5002(99)00067-7. Lung Cancer. 1999. PMID: 10568679 Clinical Trial.
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W. Manegold C, et al. Among authors: bergman b. Ann Oncol. 1997 Jun;8(6):525-9. doi: 10.1023/a:1008207731111. Ann Oncol. 1997. PMID: 9261520 Free article. Clinical Trial.
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C, Drings P, von Pawel J, Ricci S, Dornoff W, van Walree N, ten Bokkel Huinink W, Chemaissani A, Stahel P, Bergman B, Wagenius G, Sederholm C, Mattson K, Liippo K, Kellokumpu-Lehtinen P. Manegold C, et al. Among authors: bergman b. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-13-S8-17. Semin Oncol. 1997. PMID: 9207310 Clinical Trial.
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. von Pawel J, et al. Among authors: bergman b. J Clin Oncol. 2000 Mar;18(6):1351-9. doi: 10.1200/JCO.2000.18.6.1351. J Clin Oncol. 2000. PMID: 10715308 Clinical Trial.
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sörenson S; Swedish Lung Cancer Study Group. Koch A, et al. Among authors: bergman b. Eur J Cancer. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035. Epub 2011 May 10. Eur J Cancer. 2011. PMID: 21565487 Clinical Trial.
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S. von Plessen C, et al. Among authors: bergman b. Br J Cancer. 2006 Oct 23;95(8):966-73. doi: 10.1038/sj.bjc.6603383. Epub 2006 Oct 3. Br J Cancer. 2006. PMID: 17047644 Free PMC article. Clinical Trial.
703 results